Drug Discovery

#AI / data analytics / healthtech / informatics #AstraZeneca #Drug development #Funding #Research #Technology

Next wave of innovation: AstraZeneca £1bn R&D centre 

AstraZeneca has unveiled The Discovery Centre (DISC) in Cambridge, UK – a research and development (R&D) facility designed to the world’s highest environmental standards and accommodating over 2,200 research scientists.  The new £1 billion facility will include advanced robotics, high-throughput screening and AI-driven technology. It will support AstraZeneca’s focus… Read More

#News

#Covid-19 #Drug discovery #Pharmaceuticals

Newly launched antiviral nasal spray reduced Covid in ICU by 80%  

Amcyte Pharma has launched Nasitrol nasal spray for sinus irrigation in the US. In an independent clinical trial published in the peer-reviewed International Journal of General Medicine, Nasitrol reduced Covid transmission among ICU staff by nearly 80%, suggesting it could represent a safe and effective prophylaxis to prevent transmission of Covid-19.   What… Read More

#News

Handshake
#Autoimmune disease #Collaboration #Drug development #Drug targets #Funding #Partnership

Agreement to develop drug target for multiple autoimmune diseases 

Affibody partnered with ACELYRIN to develop and commercialise izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases.   Izokibep is an antibody mimetic, IL-17A inhibitor designed to overcome the limitations of monoclonal antibodies. With extraordinary potency and small molecular size, izokibep can reach high drug exposure levels through a single subcutaneous… Read More

#News

#Cancer research #Clinical trials #Drug discovery #Oncology #T-Cells #Tumours

HOOKIPA advances to Phase II trials for treatment of head and neck cancer 

HOOKIPA Pharma is advancing HB-201 to Phase II to be evaluated in combination with pembrolizumab as first or second-line treatment for Human Papillomavirus Positive 16 (HPV16+) squamous cell head and neck cancers (HNSCC).   Interim Phase I data in heavily pre-treated patients continue to show HB-200 monotherapy (both… Read More

#News

#Data #Drug development #Drug discovery #Genomics #Research study #Tuberculosis

Largest ever global TB study identifies genetic causes of drug resistance 

The Comprehensive Resistance Prediction for Tuberculosis International Consortium (CRyPTIC) research project has reportedly collected the largest ever global dataset of clinical M. tuberculosis samples from across the world consisting of 15,211 samples from 27 countries on five continents.  Using a new quantitative test for drug resistance and… Read More

#News #Trending News

#Drug discovery #Research study

New stroke clot-buster drug shows ‘exciting potential’ in mice 

A novel clot-busting drug formulated and tested by University of Manchester scientists is able to effectively restore blood flow in the brains of mice, opening the door for a safer and more effective stroke treatment, according to the study published in the journal Blood.  The compound, an… Read More

#News

#Cell therapy #Drug development #Drug discovery #Immunology

Bone marrow backup needed to tackle respiratory infections 

Scientists at the Francis Crick Institute have found how the immune system triggers an ‘emergency’ dendritic cell response during infection, with dendritic cells at the site of infection being reinforced by new cells which travel from the bone marrow.   Dendritic cells have an important role in the… Read More

#News #Trending News

#AI #AI / data analytics / healthtech / informatics #Chemistry #Drug discovery

Machine learning needs Big Data to revolutionise drug discovery

Machine learning (ML) holds the promise to revolutionise drug discovery. By integrating vast datasets into predictive models, ML will help researchers arrive at the optimal candidate compounds more quickly, disrupting the long cycle times of preclinical discovery research. DEL technology is unmatched in its ability to produce ultra-large datasets. By… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Trends & Analysis

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines

T-cell vaccines may offer “significant benefits” over current Covid-19 vaccines 

Emergex Vaccines has announced that it has received the necessary regulatory approvals to initiate a Phase I clinical trial to evaluate the safety and tolerability of its vaccine candidate for SARS-CoV-2.  The Phase I trial is a double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high… Read More

#Covid-19 #News

#Cancer research #Drug delivery #Drug development #HPV #Immunology / Virology & Vaccines

HPV vaccine proven to dramatically reduce cervical cancer 

After decades of research, the UK implemented a human papillomavirus (HPV) vaccine programme for teenage girls in 2008. Now, for the first time, a study has shown that the UK HPV vaccine programme works and will save lives, according to research funded by Cancer Research UK.  The vaccine was shown to… Read More

#News

#Drug discovery #Laboratory data

Insightful Science acquisition to expand products 

Insightful Science, the software company enabling the cloud for scientific discovery, has completed the transaction to acquire LabArchives.  LabArchives is a research data management application, serving 600,000 scientists in academic, non-profit and commercial organisations. It automates data capture, enhances collaboration, creates seamless workflows, and improves lab efficiency.  Matt Dunie,… Read More

#News

#Biologics #Drug development #Drug discovery #Immuno-oncology #Monoclonal antibodies

The potential of small molecules and biologics for new therapeutics 

Listen to this article on the DDW Podcast: Dr Seth Lederman is a physician-scientist, entrepreneur, and CEO of Tonix Pharmaceuticals. He talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.  Since its formation in 2011, Tonix Pharmaceuticals… Read More

#Business & Investment #Exclusive Content #News

#Biologics #Drug development #Flow Cytometry #Immunogenicity #Therapeutics

Cellular assays to bridge the gap in immunogenicity prediction 

Listen to this article on the DDW Podcast: Dr. Urmi Roy, Global Product Manager for Flow Cytometry Reagents, Miltenyi Biotec, explains why immunogenicity prediction is a key consideration for therapeutic development.  Biologic drugs as therapy have improved the treatment of many diseases, but their success is… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Drug design #Drug development #Immunology / Virology & Vaccines #mRNA #RNA #Synthetic biology

RNA: a coming-of-age technology for viral vaccines 

Listen to this article on the DDW Podcast: Dr Andy Lane, Commercial Director at The Native Antigen Company, discusses the development of a new generation of vaccine platforms that can be rapidly adapted to novel threats on-demand and at low cost.  Vaccines are one of the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion

#CRO #Data #Drug development

CatSci partners with Cambridge Crystallographic Data Centre 

Medicine developer CatSci has collaborated with the Cambridge Crystallographic Data Centre (CCDC). CatSci’s experimental expertise in material science combined with CCDC’s informatics tools will offer an integrated solution to customers, adding strategic value from molecule to medicine.  CCDC’s informatics-based services apply big data learnings from over one million published crystal structures to better… Read More

#News